Novo Nordisk’s India Insulin Push and Aggressive Buyback Counterbalance a Pipeline Jolt
Novo Nordisk ended the week at €43.32, a 1.29% gain on Friday that masked a slightly negative weekly…
Novo Nordisk Leverages Implant Tech, Oral Pill, and Aggressive Buyback to Counter Eli Lilly’s Moment
The competitive heat from Eli Lilly is forcing Novo Nordisk onto the front foot. The US rival’s tirzepatide…
AI and Aggressive Pricing in a Shifting Market
Novo Nordisk slashes US Wegovy HD price to $399/month, partners with OpenAI for AI integration, and faces generic…
Novo Nordisk Launches Aggressive Pricing Strategy for Wegovy Amid Restructuring
Novo Nordisk introduces a $249/month Wegovy subscription to boost patient loyalty and undercut Eli Lilly, while cutting 400…